Categories: Health

THE ADECCO GROUP Q3 2025 RESULTS

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

- Advertisement -

Strong share gains, good growth and improved profit margin

- Advertisement -

ZURICH, Nov. 6, 2025 /PRNewswire/ —

- Advertisement -

 

- Advertisement -

HIGHLIGHTS

- Advertisement -
  • Further strong market share gains, Group +375 bps and Adecco +300 bps
  • Group revenues +3.4% yoy, and +3.0% qoq, with all GBUs improving sequentially
  • Adecco GBU revenues +4.5% yoy; Europe returned to growth; Americas +20% yoy, APAC +9% yoy
  • Akkodis GBU revenues -3% yoy; German turnaround progressing well
  • LHH GBU revenues +4% yoy, led by CT +9% yoy, Ezra +59% yoy
  • Healthy 19.2% gross margin, -10 bps yoy organic, and +30 bps sequentially, reflecting business mix, firm pricing
  • Solid 3.4% EBITA margin excl. one-offs, +10 bps yoy, reflecting good operating leverage, with productivity +8% yoy
  • Operating income €160 million, +2% yoy; Net income €89 million, -2% yoy
  • Basic EPS €0.53; Adjusted EPS €0.67
  • Strong 110% LTM cash conversion; solid operating cash flow of €200 million, up €79 million yoy
  • ND/EBITDA -0.3x qoq, with net debt €220 million lower yoy

Denis Machuel, Adecco Group CEO, commented:

- Advertisement -

“Our positive trajectory has continued in mixed markets, with further market share gains and good growth. We have improved margins by 90 basis points compared to the last quarter, demonstrating strong operating leverage. We thank our teams for yet another quarter of rigorous execution. We remain on track to reach our full year margin commitment.

- Advertisement -

“We are particularly pleased with Adecco’s strong results, with solid growth across multiple regions. Akkodis improved sequentially with our German turnaround progressing well. LHH returned to growth, supported by continued strength from Career Transition.

- Advertisement -

“We look forward to sharing the evolution of our strategy and detailed value creation plans at our Capital Markets Day in London on 26 November.”

- Advertisement -

Full Press Release

- Advertisement -

Webcast Details | Investors & Analysts

- Advertisement -

For further information, please contact:

- Advertisement -


Investor Relations


investor.relations@adeccogroup.com


+41 (0)44 878 88 88


Press Office


media@adeccogroup.com


+41 (0) 79 876 09 21

Logo: https://mma.prnewswire.com/media/2608173/5604293/The_Adecco_Group_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/the-adecco-group-q3-2025-results-302606146.html

- Advertisement -
PRNW Agency

Recent Posts

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

4 days ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

1 week ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans…

1 month ago